Xilio Therapeutics (XLO) Share-based Compensation Growth (1y) (2021 - 2026)
Xilio Therapeutics (XLO) Share-based Compensation Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | 118.32% |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.68 Bn | 464.89 Bn | 1.35 Bn | -40.86% |
| 5 | Vertex Pharmaceuticals | 122.76 Bn | 115.51 Bn | 2.59 Bn | 0.18% |
| 6 | Regeneron Pharmaceuticals | 70.40 Bn | 61.65 Bn | 3.31 Bn | 5,886.05% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.88 Bn | 50.69 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | - |
| 10 | Xilio Therapeutics | 145.98 Mn | -4.32 Mn | - | 44.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.04% |
| Dec 31, 2025 | 93.27% |
| Sep 30, 2025 | -28.65% |
| Jun 30, 2025 | -10.59% |
| Mar 31, 2025 | -16.26% |
| Dec 31, 2024 | -21.45% |
| Sep 30, 2024 | -15.42% |
| Jun 30, 2024 | -16.06% |
| Mar 31, 2024 | 2.35% |
| Dec 31, 2023 | 6.34% |
| Sep 30, 2023 | -0.53% |
| Jun 30, 2023 | -33.55% |
| Mar 31, 2023 | -11.73% |
| Dec 31, 2022 | -12.36% |
| Sep 30, 2022 | 71.49% |
| Jun 30, 2022 | 170.36% |
| Mar 31, 2022 | 155.54% |
| Dec 31, 2021 | 64.76% |
| Sep 30, 2021 | 59.74% |